

Press release 2025-12-29

VibroSense Dynamics begins research collaboration with the University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust in the UK

VibroSense Dynamics AB (publ) has signed a tripartite research agreement with [the University of Sheffield](#) and [Sheffield Teaching Hospitals NHS Foundation Trust](#). The collaboration agreement concerns a research study that aims to evaluate a new treatment to relieve pain in patients with diabetes, so-called painful diabetic neuropathy (pDPN). The study will use the VibroSense Meter® II together with other methods to evaluate the treatment effect and to identify patients who may respond well to the treatment.

The study is planned to start in January 2026 with an aim to investigate whether a treatment using a so-called [Closed Loop](#) system can relieve pain caused by diabetes-related nerve damage.

Treatment using Closed Loop is costly and the goal of the study is therefore also to try to identify patients who may respond well to treatment.

– I am both happy and proud of this collaboration, not least because it involves very reputable researchers and institutions that are highly respected throughout the world. This is also a golden opportunity to prove that our VibroSense Meter® II is superior and more reliable compared to all other available Point of Care diagnostic methods.

If the study also shows a positive treatment effect, where our instrument can be used to identify susceptible patients, this could be a major step forward in establishing the VibroSense Meter® II as a standard for regular foot checks in people living with diabetes, says Toni Speidel, CEO of VibroSense Dynamics.

About painful diabetic neuropathy

Painful diabetic neuropathy (pDPN) is a common and often underdiagnosed complication of diabetes in which the patient develops neuropathic pain¹ as a direct result of nerve damage caused by diabetes. It is characterized by symptoms such as burning, tingling, cutting or electrical pain, often in the feet or legs, and can be chronic and disabling. It affects quality of life, sleep, psychological well-being and daily functioning.

A systematic review article² and meta-analysis (41 studies, almost 37,000 participants from 18 countries) estimated that pDPN occurs in approximately 46.7% of people with diabetic peripheral neuropathy (DPN).

According to epidemiological reviews, it is estimated that up to approximately 50% of all people with diabetes develop some form of peripheral neuropathy³ during their lifetime, especially with longer disease duration and poor glycemic control. Today there are about 589 million people having diabetes, according latest estimation made by [International Diabetes Federation](#) (IDF).

1. [Painful Diabetic Neuropathy](#), Pain Medicine Volume 9 Issue 6, September 2008

2. [Prevalence and risk factors of painful diabetic neuropathy](#), Diabetes Research and Clinical Practice Volume 222112099 April 2025

3. [Epidemiology of Peripheral Neuropathy](#) and Lower Extremity Disease in Diabetes, Springer Nature Volume 19, article number 86, (2019)

For more information, please contact:

Toni Speidel, CEO

VibroSense Dynamics AB (publ)

Phone: +46 40 88 026

Email: info@vibrosense.com

www.vibrosense.se

***“The new Gold Standard for reliable
detection of nerve damage”***

About VibroSense Dynamics AB (publ)

VibroSense Dynamics AB (publ) develops and sells medical devices and services to facilitate diagnosis of nerve damage in the hands and feet. The method is based on measuring and quantifying the ability to perceive vibrations applied to the skin at multiple frequencies. The company's customers include diabetes clinics, occupational healthcare providers, hospitals, point of care centers, and researchers.

Our vision that the company's products shall become a standard tool in all neurological examinations, to detect early signs of sensory changes so that patients and healthcare providers can take preventive action to avoid, reduce, or delay the onset of nerve damage in the hands and feet.